a Department of Chemical Engineering , Monash University , Clayton , Australia.
b Department of Immunology and Pathology , Central Clinical School, Monash University , Melbourne , Australia.
Expert Rev Respir Med. 2018 Nov;12(11):941-955. doi: 10.1080/17476348.2018.1523009. Epub 2018 Oct 3.
Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.
气道炎症性疾病是常见疾病，需要更好的管理和新的治疗方法。免疫疗法为解决皮质类固醇耐药性问题提供了一种解决方案。
本综述重点介绍了肺部脂多糖（革兰氏阴性细菌内毒素）介导的炎症以及用于研究相关疾病的动物模型。内毒素诱导的肺病理学通常由抗原呈递细胞（APC）启动。我们将讨论不同的 APC 亚群，包括肺树突状细胞和巨噬细胞，以及它们在应对内毒素和环境挑战中的作用。
为了对抗气道炎症，药物治疗的考虑因素应该以具有成本效益的方式改善生活质量，采用可持续和安全的策略。选择性地针对肺部的 APC 提供了一种有前途的新策略，可更好地管理和治疗炎症性肺病。
